Performance of the MAGGIC heart failure risk score and its modification with the addition of discharge natriuretic peptides

Predictive models for heart failure patients are widely used in the clinical practice to stratify patients' mortality and enable clinicians to tailor and intensify their approach. However, such models have not been validated internationally. In addition, biomarkers are now frequently measured to obtain prognostic information, and the implications of this practice are not known. In this study, we aimed to validate the model performance of the Meta‐analysis Global Group in Chronic Heart Failure (MAGGIC) score in a Japanese acute heart failure registry and further explore the incremental prognostic value of discharge B‐type natriuretic peptide (BNP) level.

[1]  S. Khoche,et al.  Left Ventricular Systolic Function , 2016 .

[2]  T. Nagai,et al.  O24-5 - Validation of the Seattle Heart Failure Model in Japanese Heart Failure Patients , 2017 .

[3]  P. Ponikowski,et al.  A multimarker multi‐time point‐based risk stratification strategy in acute heart failure: results from the RELAX‐AHF trial , 2017, European journal of heart failure.

[4]  T. Aiba,et al.  Usefulness of the Direct and/or Total Bilirubin to Predict Adverse Outcomes in Patients With Acute Decompensated Heart Failure. , 2017, The American journal of cardiology.

[5]  K. Fukuda,et al.  Current use of guideline-based medical therapy in elderly patients admitted with acute heart failure with reduced ejection fraction and its impact on event-free survival. , 2017, International journal of cardiology.

[6]  Rajeev Malhotra,et al.  Cardiopulmonary Exercise Testing in Heart Failure. , 2016, JACC. Heart failure.

[7]  T. Aiba,et al.  Prognostic significance of endogenous erythropoietin in long‐term outcome of patients with acute decompensated heart failure , 2016, European journal of heart failure.

[8]  David A. Klein,et al.  Prognostic Utility and Clinical Significance of Cardiac Mechanics in Heart Failure With Preserved Ejection Fraction: Importance of Left Atrial Strain , 2016, Circulation. Cardiovascular imaging.

[9]  K. Fukuda,et al.  Validation of the Get With The Guideline-Heart Failure risk score in Japanese patients and the potential improvement of its discrimination ability by the inclusion of B-type natriuretic peptide level. , 2016, American heart journal.

[10]  K. Fukuda,et al.  Effect of Estimated Plasma Volume Reduction on Renal Function for Acute Heart Failure Differs Between Patients With Preserved and Reduced Ejection Fraction , 2015, Circulation. Heart failure.

[11]  P. Scarborough,et al.  CardioPulse, Cardiovascular disease in Europe 2014: epidemiological update, Heart disease and stroke decline in Europe, Estimating an individual person's course of coronary artery calcification, The CardioScape Project, In memoriam , 2014 .

[12]  K. Fukuda,et al.  Prognostic impact of renal and hepatic dysfunction based on the MELD-XI score in patients with acute heart failure. , 2014, International journal of cardiology.

[13]  A. Zwinderman,et al.  Factors influencing the predictive power of models for predicting mortality and/or heart failure hospitalization in patients with heart failure. , 2014, JACC. Heart failure.

[14]  C. O'connor,et al.  Effect of B-type natriuretic peptide-guided treatment of chronic heart failure on total mortality and hospitalization: an individual patient meta-analysis , 2014, European heart journal.

[15]  Mark Woodward,et al.  Risk prediction in patients with heart failure: a systematic review and analysis. , 2014, JACC. Heart failure.

[16]  L. Lund,et al.  Predicting survival in heart failure: validation of the MAGGIC heart failure risk score in 51 043 patients from the Swedish Heart Failure Registry , 2014, European journal of heart failure.

[17]  Peter Scarborough,et al.  Cardiovascular disease in Europe 2014: epidemiological update. , 2013, European heart journal.

[18]  R. Troughton,et al.  Natriuretic peptide-guided heart failure management. , 2014, European heart journal.

[19]  Naoki Sato,et al.  Incremental value of biomarkers to clinical variables for mortality prediction in acutely decompensated heart failure: the Multinational Observational Cohort on Acute Heart Failure (MOCA) study. , 2013, International journal of cardiology.

[20]  Karl Swedberg,et al.  Predicting survival in heart failure: a risk score based on 39 372 patients from 30 studies. , 2013, European heart journal.

[21]  G. Lip,et al.  Send Orders of Reprints at Reprints@benthamscience.net Heart Failure in East Asia , 2022 .

[22]  A. Hoes,et al.  B-type natriuretic peptide and prognosis in heart failure patients with preserved and reduced ejection fraction. , 2013, Journal of the American College of Cardiology.

[23]  Li Liang,et al.  A Validated Risk Score for In-Hospital Mortality in Patients With Heart Failure From the American Heart Association Get With the Guidelines Program , 2010, Circulation. Cardiovascular quality and outcomes.

[24]  J. Cleland,et al.  The prognostic value of repeated measurement of N‐terminal pro‐B‐type natriuretic peptide in patients with chronic heart failure due to left ventricular systolic dysfunction , 2009, European journal of heart failure.

[25]  K. Dickstein,et al.  A randomised trial of a pre‐synaptic stimulator of DA2‐dopaminergic and α2‐adrenergic receptors on morbidity and mortality in patients with heart failure , 2008, European journal of heart failure.

[26]  C. Specchia,et al.  The role of plasma biomarkers in acute heart failure. Serial changes and independent prognostic value of NT‐proBNP and cardiac troponin‐T , 2007, European journal of heart failure.

[27]  D. Mozaffarian,et al.  The Seattle Heart Failure Model: Prediction of Survival in Heart Failure , 2006, Circulation.

[28]  R. Valle,et al.  B-type natriuretic peptide can predict the medium-term risk in patients with acute heart failure and preserved systolic function. , 2005, Journal of cardiac failure.

[29]  M. Martínez‐Sellés,et al.  Systolic dysfunction is a predictor of long term mortality in men but not in women with heart failure. , 2003, European heart journal.

[30]  M. Pfeffer,et al.  Effects of candesartan on mortality and morbidity in patients with chronic heart failure: the CHARM-Overall programme , 2003, The Lancet.

[31]  Harlan M Krumholz,et al.  The association of left ventricular ejection fraction, mortality, and cause of death in stable outpatients with heart failure. , 2003, Journal of the American College of Cardiology.

[32]  B. Brendorp,et al.  Long-term survival in patients hospitalized with congestive heart failure: relation to preserved and reduced left ventricular systolic function. , 2003, European heart journal.

[33]  L. Tavazzi,et al.  Clinical features and prognosis associated with a preserved left ventricular systolic function in a large cohort of congestive heart failure outpatients managed by cardiologists. Data from the Italian Network on Congestive Heart Failure. , 2002, Italian heart journal : official journal of the Italian Federation of Cardiology.

[34]  A. Takeshita,et al.  Mortality and readmission of hospitalized patients with congestive heart failure and preserved versus depressed systolic function. , 2001, The American journal of cardiology.

[35]  J. Sanderson,et al.  Plasma brain natriuretic peptide — an independent predictor of cardiovascular mortality in acute heart failure , 1999, European journal of heart failure.

[36]  D. Levy,et al.  The epidemiology of heart failure: the Framingham Study. , 1993, Journal of the American College of Cardiology.